Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARFISH: Testosterone and rHGH in FSHD
NCT03123913Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Dec 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of testosterone enanthate and somatropin in facioscapulohumeral muscular dystrophy (FSHD), sponsored by University of Rochester. Primary endpoint: Number of Participants Who Experienced an AE at 36 weeks. Started Dec 2017; status: completed.
02
Drugs
testosterone enanthatesomatropin
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT03123913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123913.